search
Back to results

Opportunstic Hepatitis C Virus Treatment (Opportuni-C)

Primary Purpose

Hepatitis C, Substance Use Disorders

Status
Completed
Phase
Not Applicable
Locations
Norway
Study Type
Interventional
Intervention
Opportunstic treatment
Standard of care
Sponsored by
University Hospital, Akershus
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Hepatitis C

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria

  • Above 18 years of age
  • HCV RNA positive
  • Inpatient at participating ward
  • Signed informed consent must be obtained and documented according to national and local regulations

Exclusion criteria:

  • Pregnancy or breastfeeding.
  • In involuntarily health care.
  • Ongoing treatment of hepatitis C.
  • Current participation in another trial that might affect the current study.
  • Any reason why, in the opinion of the investigator, the patient should not participate (e.g. not able to comply with study procedures).

Sites / Locations

  • AkershusUH

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Standard of care

Opportunistic treatment

Arm Description

Hospitalised patients with hep C are referred to the outpatient clinic at the medical department following discharge.

Hospitalised patients with hep C are opportunistically and immediately treated when hospitalized for acute care in psychiatric, addiction treatment or somatic wards

Outcomes

Primary Outcome Measures

Treatment completion
Proportion in each arm who have been dispensed the last 28 days package of HCV treatment

Secondary Outcome Measures

Sustained virological response
HCV RNA undetetctable 12 weeks after end of treatment
Reinfection
A HCV RNA strain not present at baseline is detected during or after treatment
End of treatment response
Proportion in each arm who have undetectable HCV RNA at the end of treatment

Full Information

First Posted
October 1, 2019
Last Updated
December 7, 2022
Sponsor
University Hospital, Akershus
search

1. Study Identification

Unique Protocol Identification Number
NCT04220645
Brief Title
Opportunstic Hepatitis C Virus Treatment
Acronym
Opportuni-C
Official Title
Opportunistic Treatment of Hepatitis C Virus Infection (OPPORTUNI-C): A Pragmatic Clinical Trial of Immediate Versus Outpatient Treatment Initiation Among Hospitalized Patients
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Completed
Study Start Date
October 1, 2019 (Actual)
Primary Completion Date
December 31, 2021 (Actual)
Study Completion Date
June 30, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University Hospital, Akershus

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The project will assess the effect of opportunistically treating hepatitis C virus (HCV) infection immediately when HCV-infected people who inject drugs are hospitalized for acute care in psychiatric, interdisciplinary specialized drug treatment or somatic wards. We will compare this approach with the current standard of care (SOC), which is referral to the outpatient clinic at the medical department following discharge.
Detailed Description
The overall objective is to show that opportunistic and immediate administration of HCV treatment is more efficient compared to referral-based SOC. The specific objectives are: 1) to compare the intervention and SOC groups with regards to treatment completion, treatment uptake and virologic response ; 2) to assess the rate of reinfection after successful HCV treatment; and 3) to assess the frequency of resistant associated substitutions before and after virologic treatment failure. We will use a stepped wedge design and include patients in 7 clusters Following randomization of the cluster to the immediate treatment, physicians at the participating wards will be notified in writing that for the next time period patients diagnosed with HCV infection should be treated immediately. In addition, lectures presenting the opportunistic approach will be given and the Department of Microbiology will add a brief text to the result of HCV RNA testing reminding about the opportunistic approach. In the medical and the psychiatric departments, consultants from the departments of infectious diseases or gastroenterology will prescribe immediate treatment. In the departments that provide addiction treatment, local physicians will prescribe treatment. Treatment will be prescribed in accordance with current Norwegian treatment recommendations. The intensity of care after discharge will be individualized at the discretion of the treating physician.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatitis C, Substance Use Disorders

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Pragmatic clinical trial. Cluster randomised with stepped wedge design
Masking
None (Open Label)
Allocation
Randomized
Enrollment
218 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Standard of care
Arm Type
Active Comparator
Arm Description
Hospitalised patients with hep C are referred to the outpatient clinic at the medical department following discharge.
Arm Title
Opportunistic treatment
Arm Type
Experimental
Arm Description
Hospitalised patients with hep C are opportunistically and immediately treated when hospitalized for acute care in psychiatric, addiction treatment or somatic wards
Intervention Type
Other
Intervention Name(s)
Opportunstic treatment
Intervention Description
opportunistically treating HCV infection immediately when hep C patients are hospitalized for acute care in psychiatric, addiction treatment or somatic wards
Intervention Type
Other
Intervention Name(s)
Standard of care
Intervention Description
Referral at discharge
Primary Outcome Measure Information:
Title
Treatment completion
Description
Proportion in each arm who have been dispensed the last 28 days package of HCV treatment
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Sustained virological response
Description
HCV RNA undetetctable 12 weeks after end of treatment
Time Frame
24 weeks
Title
Reinfection
Description
A HCV RNA strain not present at baseline is detected during or after treatment
Time Frame
Two years
Title
End of treatment response
Description
Proportion in each arm who have undetectable HCV RNA at the end of treatment
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria Above 18 years of age HCV RNA positive Inpatient at participating ward Signed informed consent must be obtained and documented according to national and local regulations Exclusion criteria: Pregnancy or breastfeeding. In involuntarily health care. Ongoing treatment of hepatitis C. Current participation in another trial that might affect the current study. Any reason why, in the opinion of the investigator, the patient should not participate (e.g. not able to comply with study procedures).
Facility Information:
Facility Name
AkershusUH
City
Lørenskog
State/Province
Select A State Or Province
ZIP/Postal Code
0278
Country
Norway

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
32539853
Citation
Midgard H, Finbraten AK, Malme KB, Berg-Pedersen RM, Tanum L, Olsen IC, Bjornestad R, Dalgard O. Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs. Trials. 2020 Jun 15;21(1):524. doi: 10.1186/s13063-020-04434-8.
Results Reference
derived

Learn more about this trial

Opportunstic Hepatitis C Virus Treatment

We'll reach out to this number within 24 hrs